Form 4: Apogee Therapeutics Chief Medical Officer Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 6,665 shares of common stock at $46.07 per share on December 4, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, sold 6,665 shares of the company's common stock on December 4, 2024.
- The sale was executed at a price of $46.07 per share.
- This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on September 27, 2023.
- Following the transaction, Dambkowski directly owns 260,798 shares of Apogee Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to an insider stock sale under a pre-arranged plan. It does not contain any information that would significantly impact the sentiment of the stock.
Risks
- Sales by company insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.
Industry Context
This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of trading on inside information. The sale itself does not indicate any specific change in the company's outlook or performance.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Apogee Therapeutics.
- Similar filings are regularly seen from executives at companies such as Regeneron, Amgen, and Biogen, reflecting standard practices for managing personal stock holdings.
- The volume of shares sold and the price are within the typical range for such transactions, and do not indicate any unusual activity compared to industry peers.
Stakeholder Impact
- The sale of shares by a company executive could have a minor negative impact on shareholder sentiment, although this is a routine transaction under a pre-arranged plan.
Key Dates
| Date | Description |
|---|---|
| 2023-09-27 | Date the Rule 10b5-1 trading plan was adopted. |
| 2024-12-04 | Date of the stock sale transaction. |
| 2024-12-06 | Date the Form 4 was signed. |
Keywords
Apogee Therapeutics, Carl Dambkowski, insider trading, Form 4, Rule 10b5-1, stock sale, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.